The approval came days before the FDA’s expected deadline and makes this the only PD-1 inhibitor approved for resectable ...

BeiGene has officially launched its PD-1 cancer drug Tevimbra in the U.S. more than six months after receiving a much-delayed ...

Opdivo’s approval for patients with resectable non-small cell lung cancer comes as the regulator recently raised concerns of ...

FDA approves Bristol Myers' Opdivo for resectable non-small cell lung cancer, reducing recurrence risk by 42% and showing 70% 18-month event-free survival in patients.

In 2023, BMS received a similar approval across the pond. The National Institute for Health and Care Excellence (NICE) cleared Opdivo (nivolumab) for use with platinum-based chemo to reduce the size ...

A phase 2/3 non-inferiority study compared de-escalation strategies to standard chemoradiation in patients with human ...

With a drug in advanced testing for two different indications that have spawned several blockbuster drugs, could Alumis be ...

Mean rates of colorectal cancer (CRC) screening tripled among average-risk individuals 45-49 years old after the U.S.

Hot on the tail of AstraZeneca’s Imfinzi, Bristol Myers Squibb’s PD-1/L1 inhibitor Opdivo has expanded its non-small cell lung cancer (NSCLC) net with an ...

The checkpoint inhibitor is now approved, based on CheckMate 77T findings, for neoadjuvant/adjuvant use in patients with ...

WARN notices filed with the state show more job cuts due in the health sector as companies look to cut costs and streamline ...

On Wednesday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $53.76 which represents a slight increase of $0.86 or 1.63% from the prior close of $52.9. The stock opened at ...